TY - JOUR
T1 - A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease
AU - Aisen, Paul S.
AU - Egelko, Susan
AU - Andrews, Howard
AU - Diaz-Arrastia, Ramon
AU - Weiner, Myron
AU - DeCarli, Charles
AU - Jagust, William
AU - Miller, Joshua W.
AU - Green, Ralph
AU - Bell, Karen
AU - Sano, Mary
N1 - Funding Information:
This study was supported by a grant from the Institute for the Study of Aging, as well as a grant (5 M01-RR13297) from the General Clinical Research Center Program of the National Center for Research Resources, and grants (R01-AG17861 and U01-AG10483) from the National Institute on Aging. Vitamin B 12 and vitamin B 6 tablets were kindly supplied by Rexall Sundown, Inc.
PY - 2003
Y1 - 2003
N2 - Objective: Authors determined the impact of high-dose vitamin supplements on plasma homocysteine levels in patients with Alzheimer disease (AD). Methods: Authors used an open-label trial of folic acid, vitamin B12, and vitamin B6, in combination for 8 weeks, with measurement of plasma homocysteine levels in the fasting state and after methionine-loading. A total of 69 subjects with AD were enrolled, including 33 who were taking standard multivitamin supplements; 66 were available at 8-week follow-up. Results: The high-dose vitamin regimen was associated with a significant reduction in fasting and postmethionine-loading homocysteine. Reductions were greater in the subgroup not using multivitamins, but were also significant in the multivitamin users. Conclusion: High-dose vitamin supplementation reduces homocysteine levels in patients with AD. The effect of supplementation on rate of cognitive decline will be assessed later in a randomized, double-blind study.
AB - Objective: Authors determined the impact of high-dose vitamin supplements on plasma homocysteine levels in patients with Alzheimer disease (AD). Methods: Authors used an open-label trial of folic acid, vitamin B12, and vitamin B6, in combination for 8 weeks, with measurement of plasma homocysteine levels in the fasting state and after methionine-loading. A total of 69 subjects with AD were enrolled, including 33 who were taking standard multivitamin supplements; 66 were available at 8-week follow-up. Results: The high-dose vitamin regimen was associated with a significant reduction in fasting and postmethionine-loading homocysteine. Reductions were greater in the subgroup not using multivitamins, but were also significant in the multivitamin users. Conclusion: High-dose vitamin supplementation reduces homocysteine levels in patients with AD. The effect of supplementation on rate of cognitive decline will be assessed later in a randomized, double-blind study.
UR - http://www.scopus.com/inward/record.url?scp=20244361897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20244361897&partnerID=8YFLogxK
U2 - 10.1097/00019442-200303000-00016
DO - 10.1097/00019442-200303000-00016
M3 - Article
C2 - 12611755
AN - SCOPUS:20244361897
SN - 1064-7481
VL - 11
SP - 246
EP - 249
JO - American Journal of Geriatric Psychiatry
JF - American Journal of Geriatric Psychiatry
IS - 2
ER -